<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100279'>Ulcerative colitis</z:hpo> (UC) is a disease of unknown etiology characterized by <z:mp ids='MP_0001845'>inflammation</z:mp> of the mucosa and occasionally the submucosa of the colon </plain></SENT>
<SENT sid="1" pm="."><plain>Conventional drug therapy for UC involves use of aminosalicylates, <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>, <z:chebi fb="2" ids="2948">azathioprine</z:chebi>/<z:chebi fb="1" ids="50667">6-mercaptopurine</z:chebi>, <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> and anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Alternative therapies include probiotics, <z:chebi fb="164" ids="18723">nicotine</z:chebi> and fish oil </plain></SENT>
<SENT sid="3" pm="."><plain>Drugs like tacrolimus, <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> and Trichuris suis ova are being evaluated for use in UC patients </plain></SENT>
<SENT sid="4" pm="."><plain>With the new biologic agents, new treatment options for UC continue to evolve </plain></SENT>
<SENT sid="5" pm="."><plain>In this article we will discuss the conventional drugs, the alternative therapies and the management strategies according to the severity and extent of UC </plain></SENT>
</text></document>